Eileen O'Reilly, MD
Enriched profileGastrointestinal Medical Oncologist · Memorial Sloan Kettering Cancer Center
Eileen O'Reilly is Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,337 publications with 46,371 citations (h-index 102); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 21 Oct 2026
Eileen O'Reilly, MD, is Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center. The public record shows 1,274 publications with 45,858 citations (h-index 102), centered on Pancreatic Cancer. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 16 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Pancreatic Cancer
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 120 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
Sponsor: SWOG Cancer Research Network
Industry payments
Updated 21 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202510 payments
- PFIZER INC.Program year20251 payment
- Partner Therapeutics, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.6%Antidiarrheal microorganisms30.7%Creon62%Zenpep39%Part D≥77 patientsProton pump inhibitor13.9%Pantoprazole Sodium94%Omeprazole6%Part D<11 patients+ 6 more classes in this area
Nervous system
18%Opioid Agonist7.4%Oxycodone Hcl43%Fentanyl33%Tramadol Hcl14%Hydromorphone Hcl10%Part D<11 patientsAtypical Antipsychotic3.7%Olanzapine100%Part D≥23 patients+ 3 more classes in this area
Blood & clotting
9%Factor Xa inhibitor6.5%Xarelto83%Eliquis17%Part D<11 patientsSalt solutions1.3%Sodium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 21 Oct 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
Sloan-Kettering Inst Can Research
FY2026$2,391,668P50CA257881 - Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
Sloan-Kettering Inst Can Research
FY2026$591,430P50CA257881
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials.
JCO oncology practice
Article2026 - Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.
Clinical cancer research
Article2026 - Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.
Cancer discovery
Article2026
Online presence
Updated 21 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/eileen-o-reilly-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
mskcc.org/cancer-care/doctors/eileen-o-reilly
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Mentions by others
where others cite or feature them- Other
pancan.org/press-releases/the-pancreatic-cancer-action-network-pancan-announces-new-scientific-and-medical-advisory-board-leaders-and-members
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pancan.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Trinity College, Ireland
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Scientific and Medical Advisory Board, Pancreatic Cancer Action Network (PanCAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗ - Member
ASCO Guidelines Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Member
ESMO Guidelines Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Senior/Associate Editor
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Chair
Human Research Protection Program and Institutional Review Board, Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Co-Director
Medical, David M. Rubenstein Center for Pancreatic Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Section Head
HPB & Neuroendocrine Cancers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Weill Cornell Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Media & interviews
press, podcasts and appearances- Eileen M. O'Reilly
MD, on the Challenges of Treating Patients with Pancreatic Cancer (CancerNetwork)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH